Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Elbit Imaging-M Ltd. Capital/Financing Update 2018

Mar 9, 2018

6760_rns_2018-03-09_d3a5af1c-1dca-4a99-ac3b-fb25c7006cdd.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

ELBIT IMAGING LTD. ANNOUNCES NOTES BUYBACK

Tel Aviv, Israel, March 9, 2018, Elbit Imaging Ltd. ("EI" or the "Company") (TASE, NASDAQ: EMITF) announced today, further to its press release dated February 28, 2016 regarding the Board of Directors resolution to approve new notes' Buy-Back plan of the Company's (Series I) notes ("The Notes") which are traded on the Tel Aviv Stock Exchange, that the repurchases of the following Notes was executed since February 28, 2018 to the date herein:

Note The acquiring
corporation
Quantity
purchased (Par
value)
Weighted
average price
Total amount
paid(NIS)
Series I Elbit Imaging Ltd 42,246,016 116.5 42,216,609

About Elbit Imaging Ltd.

The Company holds approximately 89.16% of Elbit Medical Ltd.'s outstanding share capital (88.68% on a fully diluted basis).

Elbit Imaging Ltd. operates in the following principal fields of business: (i) Development of shopping and entertainment centers in emerging markets; (ii) Medical industries and devices for: (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment; and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine; and (iii) land in India designated for sale to residential projects.

For Further Information:

Company Contact Ron Hadassi CEO & Chairman of the Board of Directors Tel: +972-3-608-6048

Fax: +972-3-608-6050